Rosiglitazone and Exercise in Patients With Type 2 Diabetes Mellitus

This study has been completed.

First Received: March 22, 2006 Last Updated: April 3, 2007 History of Changes

Sponsor:	Aristotle University Of Thessaloniki
Collaborator:	University of Athens
Information provided by:	Aristotle University Of Thessaloniki
ClinicalTrials.gov Identifier:	NCT00306176

Purpose

The aim of the present study is to investigate the influence of systemic exercise, rosiglitazone administration and combined pharmaceutical and lifestyle intervention on cardiovascular risk factors

Condition	Intervention	Phase
Type II Diabetes Mellitus	Drug: Rosiglitazone	Phase IV

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Official Title:	Rosiglitazone and Exercise in Patients With Type 2 Diabetes Mellitus

Resource links provided by NLM:

MedlinePlus related topics: Diabetes Exercise and Physical Fitness

Drug Information available for: Rosiglitazone Rosiglitazone Maleate

U.S. FDA Resources

Further study details as provided by Aristotle University Of Thessaloniki:

Primary Outcome Measures:

Cardiovascular risk factors alterations

Estimated Enrollment:	100
Study Start Date:	January 2005
Estimated Study Completion Date:	October 2006

Eligibility

Ages Eligible for Study:	40 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Type II diabetes mellitus
Poor glycemic control

Exclusion Criteria:

Heart failure
Renal disease
Liver disease
Cardiovascular event

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00306176

Locations

Greece
AHEPA University Hospital of Thessaloniki
Thessaloniki, Greece, 54454

Sponsors and Collaborators

Aristotle University Of Thessaloniki

University of Athens

Investigators

Study Chair:

Christos Liapis, PhD,MD

University of Athens,Greece

More Information

No publications provided by Aristotle University Of Thessaloniki

Additional publications automatically indexed to this study by National Clinical Trials Identifier (NCT ID):

Kadoglou NP, Iliadis F, Angelopoulou N, Sailer N, Fotiadis G, Voliotis K, Vitta I, Liapis CD, Alevizos M. Cardiorespiratory capacity is associated with favourable cardiovascular risk profile in patients with Type 2 diabetes. J Diabetes Complications. 2009 May-Jun;23(3):160-6. Epub 2008 Apr 16.

Kadoglou NP, Iliadis F, Liapis CD, Perrea D, Angelopoulou N, Alevizos M. Beneficial effects of combined treatment with rosiglitazone and exercise on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care. 2007 Sep;30(9):2242-4. Epub 2007 Jun 22. No abstract available.

Study ID Numbers:	1975
Study First Received:	March 22, 2006
Last Updated:	April 3, 2007
ClinicalTrials.gov Identifier:	NCT00306176 History of Changes
Health Authority:	Greece: National Organization of Medicines

Keywords provided by Aristotle University Of Thessaloniki:

rosiglitazone,exercise,cardiovascular risk factors

Additional relevant MeSH terms:

Hypoglycemic Agents
Metabolic Diseases
Physiological Effects of Drugs
Diabetes Mellitus, Type 2
Diabetes Mellitus

Endocrine System Diseases
Glucose Metabolism Disorders
Rosiglitazone
Pharmacologic Actions

ClinicalTrials.gov processed this record on February 08, 2010